News
("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback